ProBioGen and DIOSynVax partner to manufacture multivalent vaccine for haemorrhagic fever
ProBioGen, a global Contract Development & Manufacturing Organization (CDMO), is partnering with DIOSynVax to manufacture DIOS-HFVac3, a trivalent haemorrhagic fever (HF) vaccine that was developed in collaboration with Prof. Dr. Ralf Wagners team at the Institute of Medical Microbiology and Hygiene, University of Regensburg. The novel vaccine targets HF diseases caused by Ebola, Marburg, and […]